Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients.
about
Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug deliveryIntracellular antiviral activity of low-dose ritonavir in boosted protease inhibitor regimensEvaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations.Efficacy of Tat-conjugated ritonavir-loaded nanoparticles in reducing HIV-1 replication in monocyte-derived macrophages and cytocompatibility with macrophages and human neuronsPharmacokinetic modeling of plasma and intracellular concentrations of raltegravir in healthy volunteers.Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy.Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals.Does Once-Daily Raltegravir Have Any Role in the Antiretroviral Treatment?Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor.Etravirine: a review of its use in the management of treatment-experienced patients with HIV-1 infection.Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir.Prediction of Fetal Darunavir Exposure by Integrating Human Ex-Vivo Placental Transfer and Physiologically Based Pharmacokinetic Modeling.Liquid chromatography-mass spectrometry methods for the intracellular determination of drugs and their metabolites: a focus on antiviral drugs.Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients.Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment.A sensitive liquid chromatography coupled with mass spectrometry method for the intracellular and plasma quantification of raltegravir after solid-phase extraction.Limited sampling strategies for the estimation of raltegravir daily exposure in HIV-infected patients.
P2860
Q28081272-4B1D3932-5204-4748-8E01-902335634777Q33798351-6A2BCB7B-EE62-481D-9F3B-C113B946BD58Q35005018-5352E77F-EFFB-4D8F-8B93-4FE3D2F1C8E5Q35145361-B4C8159E-A799-4825-BCBA-A110FF214004Q35191450-2249BF98-8D1C-4CFE-88E1-A1BA3B077760Q36599597-F4A687ED-8729-4625-B3ED-B50EF10D9E8FQ36675900-74091F86-649E-4767-BA03-305A499DE728Q37176168-51FAEB31-9E3E-4856-AADB-32B133B9126AQ37826300-FC899325-3E92-4658-9935-663391FB65F7Q38003399-32A85F17-D9B1-4C6C-A57B-D293C628E024Q38222092-7F49D15F-EF17-4667-A086-9B401D55FC0FQ38661049-5D318B86-47AD-4675-9E82-54617C3B7B8FQ39434360-6D2D2121-3469-4311-AD5F-EF7795DA786DQ42163522-2EB515B5-B504-4B0E-A577-C3CCFB65A252Q44500239-4C93FB57-ADC3-4840-9694-CB11FD9055E5Q44660027-719F900C-ECBE-4594-8A0E-77B57AB3D4D8Q51595257-A296DB32-3492-454A-8068-35461050829A
P2860
Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Intracellular and plasma stead ...... treated HIV-infected patients.
@en
type
label
Intracellular and plasma stead ...... treated HIV-infected patients.
@en
prefLabel
Intracellular and plasma stead ...... treated HIV-infected patients.
@en
P2093
P2860
P1476
Intracellular and plasma stead ...... treated HIV-infected patients.
@en
P2093
Alwin D R Huitema
Eric C M van Gorp
Jan Willem Mulder
Jiri F P Wagenaar
Jos H Beijnen
Rob Ter Heine
P2860
P304
P356
10.1111/J.1365-2125.2010.03634.X
P407
P577
2010-05-01T00:00:00Z